InvestSMART

Tryptamine Therapeutics Limited (ASX:TYP)

ALERT: Price-sensitive ASX Announcement for TYP
Current share price for TYP : $0.034 -0.004 (-10.53%)+
Announcement
Release
31 Oct 2025 6:19PM
Price at Release
$0.038
Full Release
download
Summary
Tryptamine Therapeutics Limited (ASX: TYP) provided an update on their clinical and commercial activities for the quarter ending 30 September 2025. The company has advanced their world-first clinical trial of TRP-8803, an IV-infused psilocin, for treating Binge Eating Disorder (BED), with regulatory approvals secured and patient recruitment underway. This trial aims to evaluate the safety and efficacy of TRP-8803 in BED patients, with the first dosing anticipated in December. Additionally, Tryptamine has entered into a biomarker development agreement with key scientific collaborators to create an EEG-based platform for precision psychiatry. Financially, the company secured a $2.6 million R&D loan facility to support ongoing and future clinical programs. The company also reported a cash position of $3.94 million as of the quarter's end and is expecting significant R&D tax rebates in upcoming periods.
Key Points
  • World-first clinical trial for TRP-8803 in BED progressed with regulatory approvals.
  • Patient recruitment for BED trial initiated, with first dosing expected in December.
  • Landmark agreement for EEG-based biomarker development for precision psychiatry.
  • Secured $2.6 million R&D loan facility for FY26 activities.
  • Company's cash position at $3.94 million as of 30 September 2025.
  • Anticipated R&D tax rebates for FY24 and FY25 expenses.
  • Strengthened clinical development team with strategic appointments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.